Institutional Interest Signals Bullish Momentum for Actuate Therapeutics Stock

On November 19, 2025, HC Wainwright & Co. maintained its positive stance on Actuate Therapeutics (ACTU), underscoring confidence in the biotech company’s trajectory. The reaffirmed Buy rating reflects growing institutional attention surrounding this Nasdaq-listed firm.

Analyst Price Target Points to Significant Growth Potential

Wall Street’s consensus suggests substantial room for appreciation in Actuate Therapeutics shares. As of mid-November 2025, the average one-year price target stands at $25.50 per share, implying a potential gain of 318.03% from the recent trading price of $6.10. Analyst forecasts range between $20.20 on the conservative end and $36.75 at the high end of the spectrum. The projected non-GAAP earnings per share is estimated at -1.22 annually.

Rising Institutional Ownership Reflects Market Confidence

Actuate Therapeutics has captured the attention of the investment community, with 89 funds and institutional investors now holding positions in the company. This marks a notable 74.51% increase in the number of shareholders over the past quarter. The collective portfolio weight dedicated to ACTU has grown to 0.77% on average, representing a 48.49% expansion in institutional commitment. Total institutional shareholding increased by 3.11% to reach 11.592 million shares during the three-month period.

Major Stakeholder Activity Reveals Strategic Positioning

BIOS Capital Management maintains the largest stake, controlling 10.050 million shares representing 43.24% of outstanding equity. The firm marginally increased its position from 9.965 million shares previously, though overall portfolio allocation decreased by 19.49% in the last quarter. Voss Capital holds 286,000 shares (1.23% ownership) with no change in its quarterly holdings.

The Vanguard Total Stock Market Index Fund Investor Shares significantly expanded its exposure, raising holdings from just 4,000 to 186,000 shares—a remarkable 97.74% increase—while boosting portfolio allocation weight by 3,457.08%. Geode Capital Management reported 145,000 shares (0.63% stake), up from 118,000 shares previously, despite trimming its relative portfolio weight by 34.80%. Northern Trust’s position of 85,000 shares (0.37% ownership) represents a slight decrease from 86,000 shares, with portfolio allocation reduced by 76.88%.

These shifting institutional positions suggest sophisticated investors are closely monitoring Actuate Therapeutics’ development, with mixed positioning strategies potentially indicating selective accumulation amid the significant upside potential.